Regeneron Covid-19 therapy cuts deaths among hospitalised patients who lack antibodies: study

Published June 16, 2021
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, US. — Reuters/File
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, US. — Reuters/File

Regeneron Pharmaceuticals Inc's Covid-19 antibody cocktail reduces deaths in hospitalised patients who have not mounted their own antibody response, a large British study published on Wednesday found.

The therapy, REGEN-COV, has been granted emergency use authorisation for people with mild-to-moderate Covid-19 in the United States, but results from the Recovery trial provide the clearest evidence of its effectiveness among hospitalised patients.

It found that the antibody therapy reduced by a fifth the 28-day mortality of people admitted to hospital with Covid-19 whose immune system had not mounted an antibody response, known as seronegative.

The result translates into six fewer deaths for every 100 seronegative patients treated with the therapy, researchers said.

There was no discernible effect of the treatment on those who had generated natural antibody responses and were seropositive.

"People have been very, very sceptical, that any treatment against this particular virus would work by the time people get in hospital," Martin Landray, the joint chief investigator on the trial, told reporters.

"If you haven't raised antibodies of your own, you really would benefit from getting some," he said.

The treatment also shortened the hospital stay of those who were seronegative and reduced their chances of needing a mechanical ventilator, Landray said.

Regeneron had previously said its treatment had shown enough promise in hospitalised patients to warrant continuing its trial. This data provides the first large-scale confirmation of that assertion.

There were 9,785 patients hospitalised with Covid-19 who were randomly allocated to receive usual care plus the antibody combination therapy or just usual care, of which 30 per cent were seronegative.

The Recovery trial also showed the steroid dexamethasone and Roche's arthritis drug Actemra (tocilizumab) cut deaths in hospitalised patients.

While those treatments focus on inflammation caused by reaction to the coronavirus, Regeneron's therapy, which belongs to a class of biotech drugs called monoclonal antibodies, mimic natural antibodies the body produces to fight off the infection.

"This is the first time we've got one that's actually targeting the virus itself," Landray said, adding that it could be used along with the other treatments.

"It's not that you do one thing or another thing. These benefits are additive in these patients," he said.

Possibility for others

Other companies have been developing similar treatments.

US emergency use authorisation has been granted to antibody treatments developed by Eli Lilly and Co as well as by Vir Biotechnology Inc with GlaxoSmithKline Plc. Both are approved for use in mild-to-moderate cases.

On Tuesday, AstraZeneca said its antibody therapy had shown no evidence of protecting people from developing the disease following exposure, although other trials of its cocktail as a prevention or a treatment are ongoing.

Landray said the Recovery results should give developers of other monoclonal antibody therapies optimism that they can also be used in some hospitalised patients.

"This opens up the possibility for many, many others," he said.

"People see a few negative trials and they say 'well that'll never work' and they opt out and go off and do something else. (But) this is very, very clear, the picture that we've got from this trial."

Opinion

Coping with Covid perils
01 Aug 2021

Coping with Covid perils

Little accountability in countries such as India and Pakistan has meant whimsical decision-making.
A missing placard
Updated 01 Aug 2021

A missing placard

Scrutiny, protests, and swift police action are no guarantees of justice.
Urban flood risk
01 Aug 2021

Urban flood risk

Flood risk has been exacerbated by unchecked encroachments.
No woman’s land
Updated 31 Jul 2021

No woman’s land

We don’t just have violent men. We have a violent system.

Editorial

Necessary lockdown
Updated 01 Aug 2021

Necessary lockdown

AS the countrywide positivity ratio of Covid-19 infections crossed 8pc, Sindh imposed a nine-day lockdown effective...
01 Aug 2021

No Olympic glory

FOR about 30 minutes at the Tokyo Olympics weightlifting competition last week, Talha Talib remained in the podium...
01 Aug 2021

Preventable E-11 flooding

THE flooding on Wednesday in Islamabad’s E-11/2 sector is deserving of the shock it has spawned. The flouting of...
China-Taliban meeting
Updated 31 Jul 2021

China-Taliban meeting

WITH the government in Kabul appearing to stand on very fragile foundations, and as the clock ticks down to the ...
31 Jul 2021

Outages in Makran

IT is no surprise that people in Balochistan’s Makran Division have of late taken to the streets to protest in the...
31 Jul 2021

Reduction in polio cases

AFTER the long and tedious efforts of those running the national polio programme, there are signs that Pakistan ...